The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

The National Pharmaceutical Pricing Authority (NPPA) has sought expertise from the Indian Patent Office to assist in making ...

Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule. Methods ...

Since pneumococcal conjugate vaccines (PCVs) promise better immune responses than PPV, vaccinating at-risk adults with PCV (with or without boosters with PPV) has been proposed; however ...

An ageing population, rising antimicrobial resistance, and the ongoing threat of infectious and chronic diseases are placing ...

It is important to consolidate data on PCV10 and PCV13 impact on invasive pneumococcal disease (IPD) in all ages to determine persistent vaccine-type serotypes and the main replacement non-vaccine ...

The authors call for stronger vaccination systems, interventions, and catch-up campaigns in underserved populations.

Prioritizing disease prevention naturally requires implementing effective immunization campaigns while also fostering an ...

Immunisation helps to strengthen your child's immune system to fight diseases like polio, measles, hepatitis B, diphtheria, ...

India's drug pricing regulator, NPPA, is increasing scrutiny of pharmaceutical companies seeking price exemptions. The NPPA is collaborating with the Indian Patent Office to evaluate applications, ...